Kératoconjonctivite vernale (KCV) traitée avec succès par omalizumab

Cuadrado, M. Mozo; Banuelos, Antonio; Ecenarro, J. Etxebarria

doi:10.1016/j.jfo.2019.10.019

Cited by 1 publication

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…16 Recently, some trials have been conducted showing remarkable success with omalizumab. 17 Brief time duration of anti-IgE therapy is effective for steroid refractory VKC patients. It has opened new horizons for immune pharmacology.…”

Section: Discussionmentioning

confidence: 99%

Using Survey Scale to Assess the Reduction in Intensity of Vernal Keratoconjunctivitis Symptoms after Administration of Drugs in Tertiary Care Hospital

et al. 2022

View full text Add to dashboard Cite

Purpose:To establish the practicality of the survey scale in estimating baseline severity at the time of diagnosis and resolution of the vernal keratoconjunctivitis (VKC) symptoms after topical medication Study Design:Longitudinal survey design Place and Duration of Study: Ophthalmology department of Nishtar Medical Hospital, Multan.from June 2021 to November 2021 Methods: A total of 267 VKC (vernal keratoconjunctivitis) patients' data was filled in on preformed Google forms. Improvement in symptoms after follow-ups was recorded on it. Chi-squared test an Kruskal-Wallis test were employed to determine the statistical significance of the variables. Results:There were 52.4% females and mean age of the patients was 29.52+18.39 years. There was preponderance of patients falling under 20 years of age. At baseline, 63.3% patients were on topical steroids, while 5.6% of patients were using steroids at the second follow-up visit. The mean interval between patients’ visits to the hospital was 7.64 ± 2.086 weeks. Nonparametric Kruskal-Wallis test was used to calculate the difference in means of radial point scale scores at the baseline examination (4.47 ± 2.321) and second follow-up (1.31 ± 1.615) visits. Z-score value was 15.266 with a significance of 0.001. For patient satisfaction and resolution of symptoms at the second follow-up visit, Chi-square values were 164.75 and 119.55, respectively, with a significance of 0.001 in each case. Conclusion: The survey scale aided in quantifying disease symptoms, which can be useful in prescribing and adjusting the medications’ dosage easier.

show abstract

Section: Discussionmentioning

confidence: 99%